LTRN

Lantern Pharma Inc. (LTRN) Scenario Analysis Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Overall Score

Base Case

Liquidity remains adequate with a current ratio of 1.96 and cash ratio of 1.54.

Profitability remains deeply negative with ROA at -2.17% and ROE at -4.56%.

Valuation remains distressed, with negative earnings and cash flow yields and a low enterprise value relative to scale.

Bull Case

A turnaround would require a sustained improvement in operating margins from the current 0% TTM profile.

Balance sheet liquidity provides some room for execution, supported by positive working capital of $4.1M.

No near-term catalyst is evident from the current metrics.

Bear Case

Persistent losses and negative free cash flow increase the risk of further dilution or financing needs.

Negative book value per share and negative tangible book value indicate limited asset protection.

If operating performance does not improve, the company remains vulnerable to continued value erosion.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lantern Pharma Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →